A controlled trial of disodium cromoglycate in the treatment of Crohn's disease.
The effect of oral disodium cromoglycate (1.2 g/day) was compared with placebo in 18 patients with Crohn's disease using a double-blind cross-over trial. No improvement occurred in symptoms, signs or Crohn's disease activity index and no change in the frequency of relapses occurred. Disodium cromoglycate has not been shown to be of benefit in the management of patients with moderately active or quiescent Crohn's disease. Unexpected findings were a statistically significant, but probably unimportant, increase in mean corpuscular volume and a fall in serum urate concentration during treatment with cromoglycate.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D004205:Cromolyn Sodium